First Financial Bank Trust Division Sells 20,173 Shares of Pfizer Inc. $PFE

First Financial Bank Trust Division decreased its position in Pfizer Inc. (NYSE:PFE) by 10.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 167,677 shares of the biopharmaceutical company’s stock after selling 20,173 shares during the quarter. First Financial Bank Trust Division’s holdings in Pfizer were worth $4,064,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PFE. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new position in Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. HSBC reduced their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Finally, Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Trading Down 3.8%

NYSE PFE opened at $23.91 on Friday. The firm has a market cap of $135.94 billion, a P/E ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s 50-day moving average is $24.79 and its 200-day moving average is $24.30. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.